18:35 , May 15, 2018 |  BC Innovations  |  Translation in Brief

Sustained delivery

Researchers from Vanderbilt University School of Medicine and Baylor College of Medicine have developed a new method for stable, long-term delivery of therapeutic proteins using antigen-specific T cells whose genomes have been modified with a...
07:00 , Apr 10, 2014 |  BC Innovations  |  Cover Story

Pre-EMP-tive strike against GBM

University of California, Los Angeles researchers have treated glioblastoma in mice by inhibiting epithelial membrane protein 2 . 1 The findings open up a new indication for spinout Paganini Biopharma Inc. , which has a...
07:00 , Oct 16, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer TEK tyrosine kinase, endothelial (TEK; Tie2) Studies in mice suggest that tumor-targeting cell-based delivery of interferon-a (IFN-a) could offer...
07:00 , Jun 26, 2008 |  BC Innovations  |  Targets & Mechanisms

Prostate of Mind

Neuropeptide hormones associated with pleasure and analgesia may have an unexpected role in fighting prostate cancer, according to a report in the Proceedings of the National Academy of Sciences . 1 The study ties together...
08:00 , Nov 10, 2003 |  BC Week In Review  |  Company News

Peptimmune management update

Peptimmune Inc. , Cambridge, Mass.   Business: Autoimmune   Hired: Thomas Mathers as president, formerly president and CEO of Cell Based Delivery  ...
08:00 , Mar 31, 2003 |  BC Week In Review  |  Company News

Cell Based Delivery gene/cell therapy news

Cell Based Delivery said it will cease operations by May. The company ran into problems with preclinical trials of its ImPACT (Implantable Protein FACTory), an implantable technology based on human muscle engineered to deliver proteins...
08:00 , Dec 16, 2002 |  BC Week In Review  |  Company News

Cell Based Delivery management update

Cell Based Delivery Inc. , Providence, R.I.   Business: Hematology, Musculoskeletal   Hired: Thomas Mathers as president, CEO and a director, formerly VP and general manager of Cardion Pharmaceuticals Inc.  ...
08:00 , Dec 9, 2002 |  BC Extra  |  Company News

Cell Based Delivery names Mathers as CEO

Cell Based Delivery (Providence, R.I.), a developer of implantable protein delivery systems for hematology, musculoskeletal disorders hired Thomas Mathers as president, CEO and a director. Prior, he was VP and general manager of Cardion ....
08:00 , Jan 4, 2000 |  BC Week In Review  |  Company News

Cell Based Delivery other research news

Cell Based Delivery received a 3-year, $2 million grant from the National Institute of Standards and Technology to develop its ImPact technology to treat cardiovascular disease. ImPACT products are made from genetically engineered human cells...
08:00 , Dec 22, 1997 |  BioCentury  |  Finance

Limping

With the BioCentury 100 Price Level Index falling another 2 percent last week (it's down nearly 22 percent since early October), three IPOs fell victim to the soft market. Centocor Diagnostics, RTP Pharma, and Cerep...